CNBX: AI 评分 37/100 — AI 分析 (4月 2026)

CNBX Pharmaceuticals Inc. is a biopharmaceutical company focused on developing cannabinoid-based treatments for cancer. Their lead product, RCC-33, targets colorectal cancer, with other candidates in development for breast cancer, melanoma, and prostate cancer.

Key Facts: AI Score: 37/100 Sector: Healthcare

公司概况

概要：

CNBX Pharmaceuticals Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of cannabinoid-based treatments for various cancers, including colorectal, breast, melanoma, and prostate. Their lead product, RCC-33, is an oral capsule targeting colorectal cancer, positioning them within the competitive biotechnology landscape.

CNBX是做什么的？

CNBX Pharmaceuticals Inc., formerly known as Cannabics Pharmaceuticals Inc., was founded in 2004 and is based in Bethesda, Maryland. The company is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Their lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids designed for the treatment of colorectal cancer. In addition to RCC-33, CNBX is developing a pipeline of drug candidates targeting various forms of cancer. These include PLP-33 for the treatment of lateral spreading or sessile colorectal polyps during colonoscopy, BRST-33 to treat breast cancer, MLN-33 for the treatment of Melanoma, and PRST-33 to treat prostate cancer. The company is also developing Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome, and Cannabics CDx, an ex-vivo drug sensitivity test. CNBX Pharmaceuticals Inc. operates as a subsidiary of Cannabics Inc., focusing on innovative approaches to cancer treatment through cannabinoid-based therapies.

CNBX的投资论点是什么？

CNBX Pharmaceuticals Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on cannabinoid-based cancer treatments offers potential for significant growth, particularly if RCC-33 or other pipeline drugs demonstrate efficacy and gain regulatory approval. However, the company's small market capitalization of $0.00B and negative P/E ratio of -0.19 indicate substantial financial challenges. Successful clinical trials and securing partnerships will be critical for CNBX to realize its potential. The development and commercialization of Cannabics CDx, an ex-vivo drug sensitivity test, could provide a revenue stream and validate their technology. Investors should closely monitor clinical trial results and funding activities.

CNBX在哪个行业运营？

CNBX Pharmaceuticals Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. The company's focus on cannabinoid-based treatments differentiates it from traditional pharmaceutical companies, but also introduces regulatory and market acceptance hurdles. Competitors like ACUR, AFFY, ENDV, FLHLF, and GNLKQ are also active in the biotechnology space, some with overlapping therapeutic areas.

Biotechnology

Healthcare

CNBX有哪些增长机遇？

Expansion of Clinical Trials: CNBX has the opportunity to expand clinical trials for its lead product candidate, RCC-33, into larger patient populations and different geographical locations. Successful completion of these trials could lead to regulatory approval and commercialization, opening up a significant market opportunity in colorectal cancer treatment. The global colorectal cancer therapeutics market is projected to reach billions of dollars by 2030, presenting a substantial revenue potential for CNBX.
Development of Cannabics CDx: The development and commercialization of Cannabics CDx, an ex-vivo drug sensitivity test, represents a significant growth opportunity for CNBX. This test could help personalize cancer treatment by identifying patients most likely to respond to cannabinoid-based therapies. The market for personalized medicine and diagnostics is rapidly expanding, driven by advances in genomics and precision medicine. Successful commercialization of Cannabics CDx could generate revenue and enhance the company's reputation.
Partnerships and Collaborations: CNBX could pursue partnerships and collaborations with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its drug candidates. These collaborations could provide access to funding, expertise, and distribution networks, enhancing the company's ability to bring its products to market. Strategic alliances can significantly reduce the financial burden and timeline associated with drug development.
Expansion into New Therapeutic Areas: CNBX could expand its research and development efforts into new therapeutic areas beyond cancer, such as pain management or neurological disorders. Cannabinoids have shown promise in treating a variety of conditions, and diversifying its pipeline could reduce the company's reliance on cancer therapeutics. This expansion could open up new market opportunities and attract a broader range of investors.
Geographic Expansion: CNBX has the opportunity to expand its operations into new geographic markets, particularly in regions with favorable regulatory environments for cannabinoid-based therapies. Europe and Canada are examples of markets where cannabis-based medicines are increasingly accepted. Expanding into these markets could increase the company's revenue and global presence. Navigating international regulations will be key to success.

CNBX Pharmaceuticals Inc. is focused on cannabinoid-based treatments for cancer.
Lead product candidate RCC-33 targets colorectal cancer.
Developing drug candidates for breast cancer, melanoma, and prostate cancer.
Market Cap is $0.00B as of 2026-03-16.
P/E ratio is -0.19, indicating the company is not currently profitable.

CNBX提供哪些产品和服务？

Develop cannabinoid-based treatments for cancer.
Focus on therapies for colorectal, breast, melanoma, and prostate cancers.
Develop ex-vivo drug sensitivity tests.
Research and develop novel cannabinoid formulations.
Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
Seek regulatory approvals for their products.

CNBX如何赚钱？

Develop and patent cannabinoid-based drug formulations.
Conduct research and development to advance drug candidates through clinical trials.
Seek partnerships or out-licensing agreements with larger pharmaceutical companies.
Potentially manufacture and market approved drugs directly or through partners.

Cancer patients seeking alternative or complementary treatments.
Oncologists and other healthcare professionals.
Pharmaceutical companies interested in licensing or acquiring novel cancer therapies.
Research institutions and universities.

Proprietary cannabinoid formulations and drug delivery systems.
Intellectual property protection through patents and trademarks.
First-mover advantage in the cannabinoid-based cancer treatment market.
Expertise in cannabinoid research and development.

什么因素可能推动CNBX股价上涨？

Upcoming: Clinical trial results for RCC-33 in colorectal cancer treatment.
Upcoming: Development updates and potential commercialization of Cannabics CDx.
Upcoming: Potential partnerships or collaborations with larger pharmaceutical companies.
Ongoing: Research and development progress in cannabinoid-based therapies for various cancers.

CNBX的主要风险是什么？

Potential: Failure of clinical trials for RCC-33 or other drug candidates.
Potential: Regulatory hurdles and changing regulations for cannabinoid-based therapies.
Ongoing: Limited financial resources and difficulty securing funding.
Ongoing: Competition from established pharmaceutical companies in the cancer treatment market.
Potential: Low liquidity and high volatility due to trading on the OTC market.

CNBX的核心优势是什么？

Focus on cannabinoid-based cancer treatments.
Pipeline of drug candidates targeting various cancers.
Development of Cannabics CDx for personalized medicine.
Proprietary cannabinoid formulations.

CNBX的劣势是什么？

Limited financial resources.
Small market capitalization.
Dependence on successful clinical trials.
Regulatory hurdles for cannabinoid-based therapies.

CNBX有哪些机遇？

Expansion of clinical trials.
Partnerships with larger pharmaceutical companies.
Commercialization of Cannabics CDx.
Expansion into new therapeutic areas.

CNBX面临哪些威胁？

Competition from established pharmaceutical companies.
Regulatory changes affecting cannabinoid-based therapies.
Failure of clinical trials.
Difficulty securing funding.

CNBX的竞争对手是谁？

Accuray Incorporated — Develops and markets radiation therapy solutions for cancer treatment. — (ACUR)
Affimed N.V. — Develops immunotherapies for cancer. — (AFFY)
Endava plc — Provides technology services and consulting, potentially supporting biotech companies with their IT needs. — (ENDV)
Fennec Pharmaceuticals Inc. — Develops therapies for preventing hearing loss in children receiving chemotherapy. — (FLHLF)
Genelux Corporation — Focuses on oncolytic viruses for cancer treatment. — (GNLKQ)

Key Metrics

MoonshotScore: 37/100

Company Profile

CEO: Eyal Barad
Headquarters: Bethesda, US
Employees: 1
Founded: 2007

AI Insight

AI analysis pending for CNBX

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does CNBX Pharmaceuticals Inc. do?

CNBX Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of cannabinoid-based treatments for cancer. Their lead product candidate is RCC-33, an oral capsule targeting colorectal cancer. They are also developing other drug candidates for breast cancer, melanoma, and prostate cancer, as well as Cannabics SR for cancer anorexia-cachexia syndrome and Cannabics CDx, an ex-vivo drug sensitivity test. The company operates as a subsidiary of Cannabics Inc.

What do analysts say about CNBX stock?

AI analysis is pending for CNBX Pharmaceuticals Inc., so there is no current analyst consensus available. Given the company's $0.00B market cap, negative P/E ratio, and OTC listing, investors should conduct thorough due diligence and consider the high-risk nature of this investment. Key valuation metrics and growth considerations will depend on the progress of their clinical trials and potential regulatory approvals. The company's focus on cannabinoid-based therapies presents both opportunities and challenges.

What are the main risks for CNBX?

The main risks for CNBX Pharmaceuticals Inc. include the failure of clinical trials for their drug candidates, regulatory hurdles for cannabinoid-based therapies, limited financial resources, and competition from established pharmaceutical companies. As an OTC-listed company, CNBX also faces risks associated with low liquidity, high volatility, and less stringent financial reporting requirements. The company's dependence on successful clinical trials and regulatory approvals makes it a high-risk investment.